Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2003

View Archived Issues

BENEFIT study in early MS completes enrollment

Encouraging phase II efficacy results for NCX-701 in acute pain

XL-784 enters first-in-man safety study

DOR BioPharma pursues second indication for orBec

ES-285 enters clinical development

Good safety profile and improved glycemic control reported for balaglitazone in type 2 diabetes

Rapid onset of action reported for a novel insulin analogue

Excellent treatment compliance reported for AERx(R) iDMS among diabetic patients

Dose-dependent improvements in glycemic control in diabetic rats and humans treated with exenatide

Pramlintide acetate improves glycemic control without increasing body weight

New LXR ligands and their use described by Merck researchers

Celltech scientists design novel p38 inhibitors for arthritis and other disorders

Yamanouchi prepares and tests new vasopressin V2 ligands

Isatoribine derivatives with improved pharmacokinetics reported by Anadys

GSK-3 inhibitors, their preparation and use covered by GSK patent

New antiestrogenic agents in early development at Schering AG

Two series of beta-secretase inhibitors revealed in recent patents

Novel inhibitors of CD23 production with utility in allergy, asthma, etc.

ZP-123 prevents ischemia-induced ventricular tachycardia via effects on gap junctions

Sterix presents first dual aromatase and steroid sulfatase inhibitor

Novel aquaretic and antivasopressor agent targeting both V1a and V2 receptors

Orally active nonsteroidal progesterone receptor antagonist PRA-248 characterized

FDA approves Reyataz for HIV-1 infection

FDA approval of Striant for testosterone replacement therapy

First humanized IgE-targeting antibody therapeutic approved for asthma

Manhattan and NovaDel begin propofol lingual spray program

Emisphere and U.S. Army sign CRADA for oral anthrax vaccine

VIC-acne completes phase I safety study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...